Since PD-L1 mAb treatment is a potential novel modality in ATC [15], we analyzed the PD-L1 expression of the initially diagnosed papillary thyroid carcinoma and the later developed anaplastic thyroid carcinoma immunohistochemically. The gene discussed is CD274; the disease is differentiated thyroid carcinoma.